Product Information
NATEGLINIDE 120 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.2222 per EA under NDC 16571075909. Its NADAC has been published 227 times since Jun 1, 2022.
FDA first approved this application on Jun 18, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
120 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571075909
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NATEGLINIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205544FDA Approved
6/18/2018
TE Code
AB
On Market Since
12/16/2020
Pharmacological Classes
Price Statistics
The NADAC for NATEGLINIDE 120 MG TABLET has been published 227 times since Jun 1, 2022, and over the history we have for it it has declined 36.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2222 per EA |
|---|---|
| All-time high | $0.3574 (Jul 13, 2022) |
| All-time low | $0.2154 (Nov 22, 2023) |
| 52-week high | $0.2609 |
| 52-week low | $0.2222 |
| Median price | $0.2692 |
| Average price | $0.2739 |
| Largest weekly change | -30.0% (Nov 22, 2023) |
| Weeks tracked | 227 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
NATEGLINIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Glinide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NATEGLINIDE 120 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NATEGLINIDE 120 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.2222 per EA (NDC 16571075909), effective Sep 30, 2026.
How has the price of NATEGLINIDE 120 MG TABLET changed over time?
Over the history we have for it, the NADAC for NATEGLINIDE 120 MG TABLET has declined 36.9%. It has been tracked across 227 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for NATEGLINIDE 120 MG TABLET?
Since Jun 1, 2022, the NADAC for NATEGLINIDE 120 MG TABLET has ranged from a low of $0.2154 (Nov 22, 2023) to a high of $0.3574 (Jul 13, 2022), with a median of $0.2692 per EA.
Are there cheaper alternatives to NATEGLINIDE 120 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as NATEGLINIDE 120 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures NATEGLINIDE 120 MG TABLET?
NATEGLINIDE 120 MG TABLET (NDC 16571075909) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.